Jump to content

Search the Community

Showing results for tags 'survival'.



More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


Forums

  • COMMUNITY
    • Announcements, meetings and other resources
  • ADVANCED PROSTATE CANCER FORUMS
    • Primary hormone therapy
    • Secondary hormone therapy
    • Castrate Resistant Prostate Cancer
    • Metastatic
    • Very high risk
    • New agents
    • Every little bit helps
    • Radiation, diagnostic imaging, bones and other prostate cancer topics
    • Articles on other sites
  • MEMBER'S STORIES AND NEEDS
    • My story
    • Any suggestions?
    • The lounge

Find results in...

Find results that contain...


Date Created

  • Start

    End


Last Updated

  • Start

    End


Filter by number of...

Found 4 results

  1. During the phone-in meeting we held this morning (23 March 2018), there was discussion about Xofigo (Radium-223). The question arose of whether Xofigo gave both pain relief and longer survival. During that discussion, I mentioned that I had discussed Xofigo with American Medical Oncologist Alicia Morgans, and that this was on video. This is the video: A report on the ALSYMPCA trial of Xofigo (Radium-223) (previously called Alpharadin) can be found here. http://www.nejm.org/doi/full/10.1056/NEJMoa1213755 You can find all our videos on our YouTube channel: YouTube.com/JimJimJimJim Jim
  2. I noticed a few minutes ago that the JimJimJimJim YouTube Channel has clicked up 50,000 views. That's a lot of help and comfort that men and their partners have found in understanding advanced prostate cancer - their disease, their treatments, and the journey of others. The top topic - Gleason score in advanced prostate cancer Click the picture to view the video. Closed captions Cc for the hard of hearing. The top story - David's story - 7 years with metastatic prostate cancer Click the picture to view the video. Closed captions Cc for the hard of hearing. The top doctor - watch time - Dr Mark Moyad Click the picture to view the video. Closed captions Cc for the hard of hearing. The top doctor - views - Dr Alicia Morgans - Bones and advanced prostate cancer Click the picture to view the video. Closed captions Cc for the hard of hearing. Click the picture to view the video. Closed captions Cc for the hard of hearing. Click the picture to view the video. Closed captions Cc for the hard of hearing. Click the picture to view the video. Closed captions Cc for the hard of hearing. Click the picture to view the video. Closed captions Cc for the hard of hearing. Please continue to Like, Share and Subscribe to our YouTube Channel. It helps others find the videos they need. Jim
  3. Jim Marshall (not a doctor) said ... How many doses of the chemotherapy drug Taxotere (Docetaxel) will give longest survival? The number of doses you get depends on how your cancer is responding, and how your body is dealing with it. Six doses of Docetaxel seems to be a common aim (as in the CHARTED trial): But doctors give as many as 10 or more Docetaxel doses in a row (and may repeat that in the future if the first sessions gave a good result). No one has done a study to see if giving more than six doses in a row gives longer survival. But as part of another study, some men got more than six doses: 10 or more doses, half were still alive at 33.0 months 8 to 10 doses, half were still alive at 26.9 months 5 to 7 doses, half were still alive at 22.8 months Warning about evidence This is not evidence. It is just a hint. Researchers were looking back at what happened in a failed trial of another drug plus Docetaxel. An actual trial would be needed to provide evidence. But if your doctor keeps you on Docetaxel chemo longer, you know there is a hint it may work better. Warning one about survival numbers These men had very advanced disease - metastatic castrate resistant. Docetaxel is often given earlier in treatment, and survival figures are much higher than here. Warning two about survival numbers Doctors speak of the median survival - when half the men are still alive. That half is the men who respond to the treatment. They don't all suddenly die soon after the median time. A few may, but the survival of the others will be spread out over months and years. ... end Jim Abstract JAMA Oncol. 2016 Aug 25. doi: 10.1001/jamaoncol.2016.3000. [Epub ahead of print] Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post hoc Analysis of the Mainsail Study. de Morrée ES1, Vogelzang NJ2, Petrylak DP3, Budnik N4, Wiechno PJ5, Sternberg CN6, Doner K7, Bellmunt J8, Burke JM9, Ochoa de Olza M10, Choudhury A11, Gschwend JE12, Kopyltsov E13, Flechon A14, van As N15, Houede N16, Barton D17, Fandi A17, Jungnelius U17, Li S17, Li JS17, de Wit R1. Author information Abstract IMPORTANCE: The optimal total number of docetaxel cycles in patients with metastatic castration resistant prostate cancer (mCPRC) has not been investigated yet. It is unknown whether it is beneficial for patients to continue treatment upon 6 cycles. OBJECTIVE: To investigate whether the number of docetaxel cycles administered to patients deriving clinical benefit was an independent prognostic factor for overall survival (OS) in a post hoc analysis of the Mainsail trial. DESIGN, SETTING, AND PARTICIPANTS: The Mainsail trial was a multinational randomized phase 3 study of 1059 patients with mCRPC receiving docetaxel, prednisone, and lenalidomide (DPL) or docetaxel, prednisone, and a placebo (DP). Study patients were treated until progressive disease or unacceptable adverse effects occurred. Median OS was found to be inferior in the DPL arm compared with the DP arm. As a result of increased toxic effects with the DPL combination, patients on DPL received fewer docetaxel cycles (median, 6) vs 8 cycles in the control group. As the dose intensity was comparable in both treatment arms, we investigated whether the number of docetaxel cycles administered to patients deriving clinical benefit on Mainsail was an independent prognostic factor for OS. We conducted primary univariate and multivariate analyses for the intention-to-treat population. Additional sensitivity analyses were done, excluding patients who stopped treatment for reasons of disease progression and those who received 4 or fewer cycles of docetaxel for other reasons, minimizing the effect of confounding factors. MAIN OUTCOMES AND MEASURES: Total number of docetaxel cycles delivered as an independent factor for OS. RESULTS: Overall, all 1059 patients from the Mainsail trial were included (mean [SD] age, 68.7 [7.89] years). Treatment with 8 or more cycles of docetaxel was associated with superior OS (hazard ratio , 1.909; 95% CI, 1.660-2.194; P < .001), irrespective of lenalidomide treatment (HR, 1.060; 95% CI, 0.924-1.215; P = .41). Likewise, in the sensitivity analysis, patients who received a greater number of docetaxel cycles had superior OS; patients who received more than 10 cycles had a median OS of 33.0 months compared with 26.9 months in patients treated with 8 to 10 cycles; and patients who received 5 to 7 cycles had a median OS of 22.8 months (P < .001). CONCLUSIONS AND RELEVANCE: These findings suggest that continuation of docetaxel chemotherapy contributes to the survival benefit. Prospective validation is warranted. PMID: 27560549 DOI: 10.1001/jamaoncol.2016.3000 [PubMed - as supplied by publisher]
  4. A recent study has found that higher vitamin D Levels were associated with longer prostate cancer survival. Reference: Mondul, A. et al. Circulating 25-hydroxyvitamin D and prostate cancer survival. Cancer Epidemiology, Biomarkers & Prevention, 2016. The research has also been reported in an article by the US Vitamin D Council This article is probably easier to read than the scientific reference mentioned above.
×
×
  • Create New...